Esperion Announces Closing of $225 Million Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Esperion Therapeutics (ESPR) PT Lowered to $12 at Needham & Company, Keeps 'Buy' as Financing Extends Runway Into 2023
December 8, 2021 12:12 PM ESTNeedham & Company analyst Chad Messer lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $12.00 (from $20.00) while maintaining a Buy rating and says today's financing news addresses an overhang on the stock and extends the runway into 2023.
The analyst commented, "Last week,... More
